SpyGlass Pharma
SGP
23.90
-0.88
-3.55%
SpyGlass Pharma
US · SGP
#3415 by market cap
Listed 2026
23.90
-0.88
-3.55%
Live - 5344 symbols - heartbeat 253s ago
· 2026-10-07 19:54
After-hours
23.90
0.00%
- Market cap
- 799.41M
- P/E (TTM)i
- -14.26
- P/Bi
- 3.44
- EPSi
- -1.19
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on SGP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 94.63% -0.02pp
- Institutions
- 69
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund76.30%
Mutual Fund12.38%
Hedge Fund5.73%
Individual/Insider4.28%
Public Company0.14%
Other1.09%
Top holders as of 2026-06-30
RA Capital Management, L.P.
23.98% · 8.02M sh
New Enterprise Associates, Inc.
22.10% · 7.39M sh
Vensana Capital Management, LLC
9.90% · 3.31M sh
Sands Capital Alternatives, LLC
7.47% · 2.50M sh
Gilde Healthcare Partners BV
6.54% · 2.19M sh
Samsara BioCapital LLC
6.31% · 2.11M sh
Malik Kahook
2.61% · 873.98K sh
BlackRock
2.13% · 711.71K sh
T. Rowe Price Group, Inc.
2.02% · 674.14K sh
Vestal Point Capital, LP
2.00% · 670.00K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
45 filings tracked · 21 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 23.98% |
| New Enterprise Associates, Inc. | -- | 22.10% |
| Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | 2.61% |
| Bilal Khan | Independent Director | 0.83% |
| Patrick Mooney | Chief Executive Officer | 0.55% |
| James Dennewill | Chief Operating Officer | 0.29% |
| Scott Sandell | -- | -- |
| Geoffrey Pardo | Independent Director | -- |
| Mohamad Makhzoumi | -- | -- |
| Elizabeth O'Farrell | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-02-08 | New Enterprise Associates, Inc. | -- | Private Acquisition | +937,500 | $16.00 |
| 2026-02-08 | New Enterprise Associates, Inc. | -- | Derivative Exercise and Retained | +6,454,801 | -- |
| 2026-02-08 | RA Capital Management, L.P. | -- | Private Acquisition | +3,690,000 | $16.00 |
| 2026-02-08 | RA Capital Management, L.P. | -- | Derivative Exercise and Retained | +4,331,117 | -- |
| 2026-02-08 | Gilde Healthcare Partners BV | -- | Private Acquisition | +312,500 | $16.00 |
| 2026-02-08 | Gilde Healthcare Partners BV | -- | Derivative Exercise and Retained | +1,875,013 | -- |
| 2026-02-08 | Bilal Khan | Independent Director | Private Acquisition | +135,000 | $16.00 |
| 2026-02-04 | Scott Sandell | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Geoffrey Pardo | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Mohamad Makhzoumi | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Elizabeth O'Farrell | -- | Other Derivative Acquisition | +13,700 | $16.00 |
| 2026-02-04 | Elizabeth O'Farrell | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | RA Capital Management, L.P. | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Jean-Frederic Viret | Chief Financial Officer | Other Derivative Acquisition | +17,500 | $16.00 |
| 2026-02-04 | Jean-Frederic Viret | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-02-04 | Kirk Nielsen | -- | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Michael Dybbs | Independent Director | Other Derivative Acquisition | +27,400 | $16.00 |
| 2026-02-04 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Other Derivative Acquisition | +105,000 | $16.00 |
| 2026-02-04 | Malik Kahook | Co-Founder, President, Chief Medical Officer & Executive Chairman | Initial Statement of Beneficial | 0 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.